Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Cancer Res Treat. 2005 Feb;37(1):20-3. doi: 10.4143/crt.2005.37.1.20. Epub 2005 Feb 28.
This study was designed to investigate the validity of a single immunochemical fecal occult blood test (FOBT) for detection of colorectal neoplasia.
A total of 3,794 average-risk screenees and 304 colorectal cancer patients admitted to the National Cancer Center, Korea, between May 2001 and November 2002, were studied prospectively. All screenees and admitted patients underwent FOBT and total colonoscopic examinations. Stools were self-collected, and examined using an immunochemical fecal occult blood test (OC-hemodia, Eiken Chemical Co. Tokyo, Japan) and an OC-sensor analyzer(R) (Eiken Chemical Co. Tokyo, Japan).
Of the 3,794 asymptomatic screenees, the colonoscopy identified colorectal adenomas and cancers in 613 (16.2%) and 12 (0.3%) subjects, respectively. The sensitivities of a single immunochemical FOBT for detecting colorectal cancers and adenomas in screenees were 25.0 and 2.4%, respectively. The false positive rate of FOBT for colorectal cancer in screenees was 1.19%. For the total 316 colorectal cancer cases (including 12 cases from screenees), the FOBT sensitivities according to the T-stage were 38.5, 75.0%, 78.9 and 79.2% for T1, 2, 3 and 4 cancers, respectively. The sensitivities according to the Dukes stages A, B and C were 63.4, 79.3 and 78.6%, respectively.
The sensitivities of a single immunochemical FOBT for detecting colorectal cancers and adenomas in screenees were 25.0 and 2.4%, respectively. The sensitivities of FOBT were about 80% for Dukes B or C colorectal cancers and 63.4% for Dukes A.
本研究旨在探讨单次免疫化学粪便潜血试验(FOBT)检测结直肠肿瘤的有效性。
2001 年 5 月至 2002 年 11 月,共有 3794 名平均风险筛查者和 304 名韩国国家癌症中心的结直肠癌患者参与了前瞻性研究。所有筛查者和入院患者均接受 FOBT 和全结肠镜检查。采集粪便样本,使用免疫化学粪便潜血试验(OC-hemodia,Eiken Chemical Co.,东京,日本)和 OC-sensor 分析仪(R)(Eiken Chemical Co.,东京,日本)进行检测。
在 3794 名无症状筛查者中,结肠镜检查发现结直肠腺瘤和癌症分别在 613 例(16.2%)和 12 例(0.3%)患者中。单次免疫化学 FOBT 检测结直肠癌和腺瘤的敏感性分别为 25.0%和 2.4%。FOBT 对筛查者结直肠癌的假阳性率为 1.19%。对于总共 316 例结直肠癌病例(包括 12 例来自筛查者),FOBT 敏感性按 T 分期分别为 T1、2、3 和 4 期癌症的 38.5%、75.0%、78.9%和 79.2%。按 Dukes 分期 A、B 和 C 的敏感性分别为 63.4%、79.3%和 78.6%。
单次免疫化学 FOBT 检测筛查者结直肠癌和腺瘤的敏感性分别为 25.0%和 2.4%。FOBT 的敏感性约为 Dukes B 或 C 期结直肠癌的 80%和 Dukes A 期的 63.4%。